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Abstract
Background: Cross-sectional studies suggested that allergy prevalence in childhood is higher
in boys compared to girls, but it remains unclear whether this inequality changes after puberty.
We examined the sex-specific prevalence of asthma and rhinitis as single and as multimorbid
diseases before and after puberty onset in longitudinal cohort data.
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Methods: In six European population-based birth cohorts of MeDALL, we assessed the out-
comes: current rhinitis, current asthma, current allergic multimorbidity (ie, concurrent asthma
and rhinitis), puberty status and allergic sensitization by specific serum antibodies (im-
munoglobulin E) against aero-allergens. With generalized estimating equations, we analysed the
effects of sex, age, puberty (yes/no) and possible confounders on the prevalence of asthma
and rhinitis, and allergic multimorbidity in each cohort separately and performed individual par-
ticipant data meta-analysis.
Findings: We included data from 19 013 participants from birth to age 14-20 years. Current
rhinitis only affected girls less often than boys before and after puberty onset: adjusted odds
ratio for females vs males 0.79 (95%-confidence interval 0.73-0.86) and 0.86 (0.79-0.94),
respectively (sex-puberty interaction P = .089). Similarly, for current asthma only, females were
less often affected than boys both before and after puberty onset: 0.71, 0.63-0.81 and 0.81,
0.64-1.02, respectively (sex-puberty interaction P = .327). The prevalence of allergic multimor-
bidity showed the strongest sex effect before puberty onset (female-male-OR 0.55, 0.46-0.64)
and a considerable shift towards a sex-balanced prevalence after puberty onset (0.89, 0.74-
1.04); sex-puberty interaction: P < .001.
Interpretation: The male predominance in prevalence before puberty and the “sex-shift”
towards females after puberty onset were strongest in multimorbid patients who had asthma
and rhinitis concurrently.
K E YWORD S
allergic multimorbidity, asthma, birth cohort, puberty, rhinitis
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1 | INTRODUCTION
The prevalence of two of the most common chronic diseases glob-
ally, asthma and rhinitis, remains at a high level or is still increasing
in some parts of the world.1-3 At around puberty, considerable sex-
specific differences in the prevalence of allergic diseases have been
identified.4-6 For asthma, the prevalence is higher in boys than in
girls before puberty, but after puberty, there is a female predomi-
nance persisting in adulthood.7-10
In rhinitis, sex-specific prevalence differences before and after
puberty onset are less clear.11 A recent meta-analysis of cross-sec-
tional population-based studies suggested a “sex-switch” around
puberty from male to female predominance in rhinitis preva-
lence.12 However, longitudinal sex-specific evaluations from early
childhood to adolescence regarding rhinitis as well as asthma
prevalence are lacking. Long-term birth cohort studies are essential
to understanding the life course and childhood predictors of aller-
gies including sex-specific differences.13 As the statistical power of
individual cohorts is often insufficient to allow stratified analy-
ses,14 the European Commission funded MeDALL (Mechanisms of
the Development of ALLergy; EU FP7-CP-IP; Project No: 261357;
2010-2015) with the aim to integrate 14 European birth cohorts
including 44 010 participants for combined and harmonized
analyses.15
This large data set allowed examining a potential sex-shift in the
prevalence of less common but more severe allergic phenotypes
such as multimorbidity of asthma and rhinitis and their association
with and without allergen-specific immunoglobulin E (IgE) antibodies
with the sufficient statistical power.15
Asthma and rhinitis are both heterogeneous diseases with many
forms and phenotypes of different aetiologies; thus, we differenti-
ated between asthma only and rhinitis only as single entities and
multimorbidity.15,16
In the present analyses, we aimed to examine and compare a
possible “sex-shift” in prevalence of asthma, rhinitis and multimorbid-
ity (asthma and concurrent rhinitis) during puberty using the pooled
MeDALL cohort data.
2 | METHODS
2.1 | Study design, setting and included birth
cohorts
This study is based on the six older population-based birth
cohorts from the MeDALL project.15,17 We chose the following
inclusion criteria: (i) at least one prospective assessment of asthma
and rhinitis before puberty (ie, from birth to 10 years of age) and
after possible puberty onset (11-18 years); (ii) at least one assess-
ment of allergic sensitization based on specific antibodies against
aero-allergens in serum; (iii) at least one prospective assessment
of the puberty status at 10 years or older. The included birth
cohorts were PIAMA (The Netherlands), BAMSE (Sweden), DARC
(Denmark) and MAS, GINIplus and LISAplus (all Germany). All par-
ticipating birth cohorts had obtained ethical approval from their
local review boards. Recruitment, study design and data collection
for the birth cohort studies have been described in detail previ-
ously.18-22
Information on health outcomes and puberty status has been col-
lected at several time points. The number of time points and exact
ages of the participants at follow-up differed between cohorts.
When combining the cohorts, we had data for a total of 14 possible
follow-up time points (Table S1).
A panel of experts within the MeDALL consortium followed a
stringent process23 for data harmonization between the participating
cohorts. For each variable to be harmonized, a reference definition
was agreed and each cohort then evaluated how their own cohort
definition matched the reference definition as complete, partial or
impossible. All single evaluations were then reviewed in a joint work-
shop to create the final harmonized data set.
2.2 | Outcome variables
2.2.1 | Primary outcomes
We defined three primary outcome measures: current asthma only,
current rhinitis only and current allergic multimorbidity.
Current asthma only
“Current asthma only” was defined as a positive answer to at least
two of the three following questions:
• “Has your child ever been diagnosed by a doctor as having
asthma?”
• “Has your child (/Have you) taken any medication for asthma (in-
cluding inhalers, nebulizers, tablets or liquid medicines) or breath-
ing difficulties (chest tightness, shortness of breath) in the last
12 months?”
• “Has your child (/Have you) had wheezing or whistling in your
chest at any time in the last 12 months?”24
and a negative “current rhinitis” status. If two of these three ques-
tions were answered with “no” at the respective follow-up, asthma
status was negative.
Current rhinitis only
The occurrence of “current rhinitis only” at the respective follow-
up assessment was defined by a positive (parent or self-reported)
answer to the question “Has your child had/Did you have prob-
lems with sneezing, or a runny, or blocked nose when s/he/you
did not have a cold or flu in the past 12 months?” (yes/no) based
on the International Study of Asthma and Allergy in Childhood
(ISAAC)24 and a negative current asthma status. A negative
answer to the question above defined a negative current rhinitis
status.
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Current allergic multimorbidity
A positive “current allergic multimorbidity” status was defined as
concurrent asthma and rhinitis. If either rhinitis or asthma was nega-
tive, allergic multimorbidity status was defined as negative.
2.2.2 | Secondary outcomes
To investigate possible effects of puberty status on allergic sensitiza-
tion, we included the following six secondary outcomes:
• “IgE-associated current rhinitis”
• “Non-IgE associated current rhinitis”
• “IgE-associated current asthma”
• “Non-IgE associated current asthma”
• “IgE-associated current allergic multimorbidity (asthma and rhini-
tis)”
• “Non-IgE associated current allergic multimorbidity (asthma and
rhinitis)”.
A positive allergic sensitization status was defined as specific
immunoglobulin E (IgE) ≥ 0.35 kU/L in serum against at least one
common aero-allergen (dog, cat, house dust mite or birch pollen, as
they were assessed in all included cohorts) at the same follow-up at
which the clinical phenotypes were assessed or, if serum samples
were missing, at the preceding follow-up. A negative allergic sensiti-
zation status was defined as s-IgE < 0.35 kU/L against all four com-
mon aero-allergens.
As a sensitivity analysis, we defined the six secondary outcomes
including sensitization status based on IgE against food and aero-
allergens, defined as s-IgE ≥ 0 .35 kU/L against at least one common
food (cow’s milk, hen’s egg, peanut) or aero-allergen. A negative
allergic sensitization status was defined as s-IgE < 0.35 kU/L against
all of the seven allergens.
2.3 | Definition of main exposure variable puberty
Puberty categories were defined using the Puberty Development
Scales (PDS).25,26 For boys, the following items were included: (i)
body hair growth, (ii) voice change and (iii) facial hair growth. For
girls, the Puberty Category Scores (PCS) was based on (i) body hair
growth, (ii) breast development and (iii) menstruation.
For each item (except menstruation) four response categories
indicate the extent of puberty from “not yet started” up to
“seems complete”. These were coded with values of 1 to 4 and
summed up for each participant. According to these sum scores
(and the stage of menstruation in girls) PCS was defined as Pre-
pubertal, Early Pubertal, Midpubertal, Late Pubertal, Postpubertal.
For the final binary analysis variable ‘puberty’ Midpubertal, Late
Pubertal, and Postpubertal were considered as a positive puberty
status.
Additionally, to gain more insight into possible effects of the
age at puberty-onset in relation to the sex-shift of allergic diseases
during puberty, we conducted a sensitivity analysis including the
information of the time point of puberty-onset by using the age
period 10-12 years for early and 13-16 years for late puberty-
onset.
2.4 | Definition of possible confounders
Based on results from previous studies, we considered the following
variables in the analyses as possible confounders: age (categorical
(for all cohort-specific models except for MAS) or continuous (for
models in the MAS cohort and in pooled data set)—depending on
number of available follow-ups per cohort), history of parental
allergies (yes = at least one parent with asthma and/or rhinitis
diagnosis/no = two nonallergic parents) and maternal smoking during
pregnancy (yes/no).27,28
2.5 | Statistical methods
For categorical variables, absolute and relative frequencies are pre-
sented. Results of all descriptive analyses are presented separately
by cohort and pooled for all cohorts and sex. We pooled relative fre-
quencies using random-effect meta-analyses.
We used generalized estimating equations (GEE) to estimate
adjusted odds ratios (OR) and 95% confidence interval (CI) for the
associations of the primary and secondary outcome variables with
sex and puberty (and the interaction thereof) adjusting for the possi-
ble confounders described above, and age as the longitudinal time
variable. The focus was on the interaction of puberty and sex as an
indicator of sex-specific changes in outcome prevalence before vs
after puberty onset. With GEE models, outcomes and exposure of
the participants are analysed over time, taking the longitudinal
design and thus the repeated measurements of one individual, which
are not independent of each other, into account.
Initially, we pooled the harmonized cohort data sets to perform a
one-stage Individual Participant Data (IPD) meta-analysis.29 We used
the GEE model described above on the combined data set of all
cohorts with a birth cohort identifier variable included as an addi-
tional covariable in the model with participants nested in cohorts to
account for the clustering in each cohort.
Additionally, as a comparative sensitivity analysis, we conducted
a two-stage IPD meta-analysis, which consisted of the estimation of
the adjusted odds ratios with the GEE model described above for
each cohort separately as first stage and a subsequent random-effect
meta-analyses with the inverse-variance method combining as sec-
ond stage the adjusted effect estimates from all cohorts. Hetero-
geneity across the studies was assessed using the chi-squared Q-
statistic and I2.30
All our analyses are of explorative nature and we did not adjust
for multiple testing. Missing values were not imputed. Thus, the
number of included participants varied for more complex analyses
including several variables and different number of missings per
variable. We performed the meta-analyses in R version 3.1.2
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(R Foundation for Statistical Computing) and all other analyses with
SAS version 9.4 (SAS Institute, Cary, NC, USA).
3 | RESULTS
3.1 | Description of cohorts
We included six birth cohorts with a total of 19 013
recruited participants: PIAMA (the Netherlands, 1996, n = 3963),
BAMSE (Sweden, 1994, n = 4089), DARC (Denmark, 1998, n = 562)
and three German birth cohorts (GINIplus, 1995, n = 5991; LISAplus,
1997, n = 3094; and MAS, 1990, n = 1314). We used data from
birth to age 14-20 years (depending on the cohort). The number of
observations used varied over follow-up time points due to dropouts
and nonresponse. For analyses concerning the three GEE models for
the primary outcomes, all necessary information (at least at one time
point) was available for 14 533 participants.
3.2 | Puberty and exposure variables
In total, approximately 50% of the participants were female. Pub-
erty started earlier in girls than in boys (eg, 62% vs 3% at age 11
in PIAMA, the Netherlands) with boys catching up in later teenage
years (across the cohorts, except DARC), about 90%-99% of the
participants had reached puberty according to our definition at
the last included follow-up. Exposures such as self-reported paren-
tal allergies (ever) and maternal smoking differed slightly between
the cohorts, but not considerably between boys and girls
(Table 1).
3.3 | Prevalence of primary outcomes
3.3.1 | Current rhinitis only
Prevalence of current rhinitis only (ie, without coexisting asthma)
varied between the cohorts. Among boys, it was generally higher
than girls in earlier childhood, but this difference became smaller
with increasing age (Figure 1; Table S1).
3.3.2 | Current asthma only
Prevalence of current asthma only differed slightly between the
cohorts, with the highest prevalence in BAMSE across the follow-
ups. At a younger age, more boys than girls had asthma but in
teenage years these differences were smaller or even disappeared
such as in GINIplus and BAMSE (Figure 2; Table S2).
3.3.3 | Allergic multimorbidity
Current allergic multimorbidity prevalence was higher among boys
than girls especially in earlier childhood. These differences decreased
as the participants grew older to smaller or even no differences
between males and females (Figure 3; Table S3).
3.4 | Primary outcomes in relation to puberty
3.4.1 | Current rhinitis only
For current rhinitis only, the male predominance before puberty
remained but was less pronounced after the onset of puberty. There
was some degree of heterogeneity among the cohorts after puberty
onset (I2 = 39.6%) but not before puberty (Table 2). The pooled one-
stage IPD meta-analysis also indicated this trend towards a female-
male ratio decline (interaction sex*puberty onset P = .089) (Figure 4).
3.4.2 | Current asthma only
For current asthma only, we found a male predominance before pub-
erty that decreased slightly after puberty onset. There was no
heterogeneity among the cohorts (Table 2; Figure 4).
3.4.3 | Allergic multimorbidity
The strongest male predominance before puberty was found for
allergic multimorbidity (OR: 0.55, 95%-CI 0.46-0.64). Furthermore,
this outcome showed a clear shift towards a sex-balanced preva-
lence after puberty onset (0.89, 0.74-1.07), sex-puberty onset inter-
action term P < .001 (Figure 4). There was no considerable
heterogeneity among the cohorts (Table 2).
3.5 | Sensitivity analyses: two-stage IPD meta-
analyses
The additional two-stage IPD meta-analyses, which we performed as
a sensitivity analyses, showed similar effect estimates for all three
primary outcomes as the pooled one-stage IPD approach. The two-
stage approach also allowed us to calculate I2 for the assessment of
potential heterogeneity between the cohorts. There was no consid-
erable statistical heterogeneity for the primary outcomes apart for
current rhinitis only with some moderate heterogeneity (Table 2).
3.6 | Sensitivity analyses: differentiating early and
late puberty onset
Differentiating between early (age 10-12 years) and late puberty
onset (age 13-16 years) did not change the effect estimates and the
corresponding P-values for the interaction “pubertytime*sex” consid-
erably compared to our primary analyses (Table S5).
3.7 | IgE- and non-IgE associated outcomes
3.7.1 | IgE- and non-IgE associated current rhinitis
only and current asthma only
Prevalence estimates of IgE-associated current rhinitis only and
asthma only were higher in male than in female participants before
and to a lesser extent after puberty onset.
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In contrast, both non-IgE associated rhinitis only and asthma only
showed sex-balanced prevalence estimates before puberty and a
slight female predominance in the prevalence after puberty onset,
corresponding sex-puberty interaction terms P = .074 and P = .141,
respectively (Table 2).
3.7.2 | IgE- and non-IgE associated allergic
multimorbidity
For IgE-associated allergic multimorbidity, we found a sex-shift from
a strong male predominance before puberty towards a sex-balanced
prevalence after puberty onset (sex-puberty interaction term
P < .001). Similarly, non-IgE associated allergic multimorbidity
showed also a sex-shift in the prevalence from a clear male predomi-
nance before puberty towards a sex-balanced occurrence of this
phenotype after puberty onset (Table 2).
3.8 | Sensitivity analyses: allergic sensitization
including IgE against aero- and food allergens
Including IgE against the common aero- and food allergens showed
similar effect estimates for IgE- and non-IgE associated current
rhinitis only, current asthma only and allergic multimorbidity com-
pared to our primary definition of allergic sensitization status based
only on common aero-allergens (Table S6).
4 | DISCUSSION
4.1 | Key results
Our individual participant data meta-analyses of six large European
birth cohorts showed a strong male predominance before puberty
for the prevalence of current allergic multimorbidity and to a les-
ser extent for current rhinitis and current asthma as single enti-
ties. After puberty onset, the sex-specific odds ratio shifted
towards females in all phenotypes resulting in a rather sex-
balanced prevalence for asthma only and particularly for allergic
multimorbidity.
Considering allergic sensitization status, we found that for IgE-
associated rhinitis only and asthma only, the clear male predomi-
nance decreased slightly, but remained significant after puberty
onset, whereas for IgE-associated multimorbidity, we found a much
stronger shift towards females with rather sex-balanced prevalence
after puberty onset.
F IGURE 1 Sex-specific prevalence with
95% CI of current rhinitis only (on a
logarithmic scale) in six European birth
cohorts by age
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The non-IgE associated (single and multimorbid) phenotypes
showed a slight female predominance after puberty onset, which
was strongest for non-IgE associated rhinitis.
4.2 | Strengths and limitations
Based on validated puberty assessments, this is the first longitudi-
nal evaluation of birth cohort data assessing the sex-shift in
prevalence at around puberty not only for rhinitis or asthma as
single entities, but also for allergic multimorbidity. We combined
prospectively collected data from six European birth cohorts from
early childhood through adolescence up to age 20. For the IPD
meta-analysis, we used pooled raw original data, which allowed us
to define outcome and exposure variables, confounding variables
and interactions consistently across the cohorts. Previous sex-shift
evaluations had almost exclusively cross-sectional designs and used
heterogeneous methods. This limited the comparability of sex-
ratios before and after puberty onset between these studies,
because the participants were not the same in the two groups (ie,
before and after puberty). Due to the longitudinal character of the
data in our study with homogeneous prospective assessments,
comparability of sex-specific prevalence estimates before and after
puberty onset can be considered more robust. Our findings gained
external validity from the combination of several large cohorts
showing similar results in different European regions and recruit-
ment settings.
One limitation of (birth) cohort studies is that they are dynamic
and prone to missing values during the course of repeated follow-up
assessments as some participants, in particular teenagers, drop out
or participate irregularly. This may cause selection bias and poten-
tially limits the representativeness of the results.
Furthermore, at the time of the last follow-up included in our
present analyses, some participants (PIAMA, the Netherlands, and
DARC, Denmark) were just 14 years old and may not have reached
puberty. The proportion of girls not in puberty was 0.2% (PIAMA)
and 4.1% (DARC), which was comparable to the other cohorts with
older participants at last follow-up, and for boys approximately 35%
(DARC) and 15% (PIAMA). We cannot rule out a potential bias, espe-
cially if single cohorts will be analysed separately, but consider this
risk of bias negligible in our large meta-analyses, where the absolute
number of prepubertal participants at the last follow-up was compar-
atively small (eg, DARC represented <3% of all children recruited for
F IGURE 2 Sex-specific prevalence with
95% CI of current asthma only (on a
logarithmic scale) in six European birth
cohorts by age
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the 6 birth cohorts in total). We aimed to examine possible effects
of the age at which puberty started by defining two main categories
of early (age 10-12 years) and late onset (age 13-16 years) based on
the assessment time points of the cohorts. We did not find a consid-
erable impact of the timing of puberty with this approach. To anal-
yse this aspect in more detail than in our sensitivity analysis was not
F IGURE 3 Sex-specific prevalence with
95% CI of current allergic multimorbidity
(on a logarithmic scale) in six European
birth cohorts by age
TABLE 2 Adjusted odds ratiosa with 95% confidence intervals (CI) for sex effect (female vs male) before and after puberty for two-stage
meta-analysis incl. assessment of heterogeneity among the cohorts using I2
Outcome
Two-stage IPD meta-analysis
Adjusted ORa (95%-CI)
Heterogeneity I2
Before puberty onset After puberty onset
Current rhinitis only 0.78 (0.72-0.84) I2 = 0% 0.90 (0.80-1.02) I2 = 39.6%
Current asthma only 0.71 (0.62-0.82) I2 = 0% 0.82 (0.64-1.06) I2 = 4%
Current allergic multimorbidity 0.54 (0.46-0.65) I2 = 11% 0.85 (0.71-1.03) I2 = 0%
IgE-associated current rhinitis only (without asthma) 0.66 (0.52-0.84) I2 = 54.9% 0.75 (0.66-0.86) I2 = 22.1%
IgE-associated current asthma only (without rhinitis) 0.53b (0.40-0.70) I2 = 0% 0.62b (0.42-0.91) I2 = 2%
IgE-associated current allergic multimorbidity 0.52 (0.42-0.66) I2 = 0% 0.84 (0.68-1.05) I2 = 0%
Non-IgE associated current rhinitis only (without asthma) 0.94 (0.83-1.06) I2= 0% 1.17 (1.02-1.34) I2 = 0%
Non-IgE associated current asthma only (without rhinitis) 0.84b (0.69-1.03) I2 = 0% 1.17b (0.81-1.72) I2 = 0%
Non-IgE associated current allergic multimorbidity 0.73b (0.42-1.27) I2 = 57.8% 0.97b (0.53-1.79) I2 = 34.6%
aAdjusted for age, parental allergy and maternal smoking during pregnancy.
bDue to small prevalence in some cohorts not including all cohort estimators.
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possible because the cohorts differed in terms of the ages and fol-
low-up intervals at which pubertal stage was assessed.
4.3 | Comparison to other studies
Pinart et al found a sex-switch for current (allergic) rhinitis preva-
lence from male to female predominance in their recent meta-analy-
sis of published cross-sectional studies comparing childhood
populations with adolescent and adulthood populations including
mainly middle-aged participants. Participants of all birth cohorts
included in our IPD meta-analyses except one had not reached
adulthood yet. Therefore, we may have only found an indication
towards a sex-shift but not a complete “sex-switch” in the preva-
lence of rhinitis as Pinart et al.’s analyses suggested. However, our
findings point towards such an effect. Pinart et al.’s study differed
further from ours as their meta-analyses focused on cross-sectional
studies that mostly did not measure IgE sensitization, thus could not
distinguish between IgE-associated and non-IgE associated rhinitis
phenotypes.31,32 Furthermore, the differentiation between rhinitis as
a single or as part of a multimorbid phenotype was not made by
Pinart et al12 either.
In the Isle-of-Wight birth cohort study from the UK, which
started in 1989, prevalence of sensitized and nonsensitized rhinitis
in childhood and early adulthood showed a similar pattern to our
findings. Concerning the differences in sensitization status of rhinitis
patients, they showed a male predominance in rhinitis during early
childhood as well as at 18 years of age only in subjects with rhinitis
who were sensitized. For nonsensitized rhinitis, females in the UK
cohort had a significantly higher prevalence at age 18 years.33 Our
results showed sex-balanced prevalence both before and after
0.5 1 2
Male Predominance Female Predominance
0.79
0.86
0.71
0.81
0.55
0.89
0.69
0.76
0.56
0.68
0.56
0.91
0.99
1.13
0.81
1.07
0.63
1.04
[0.73; 0.86]
[0.79; 0.94]
[0.63; 0.81]
[0.64; 1.02]
[0.46; 0.64]
[0.74; 1.07]
[0.60; 0.80]
[0.67; 0.86]
[0.42; 0.74]
[0.48; 0.99]
[0.44; 0.71]
[0.73; 1.13]
[0.87; 1.12]
[1.00; 1.29]
[0.67; 0.97]
[0.75; 1.54]
[0.47; 0.85]
[0.71; 1.53]
IgE-associated current
rhinitis only (N = 10 575)
Before puberty
After puberty 
Before puberty
After puberty 
IgE-associated current allergic 
multimorbidity (N = 10 575) 
Before puberty
After puberty 
Non–IgE associated current
rhinitis only (N = 10 575)
Non–IgE associatedcurrent 
asthma only (N = 10 575)
Non–IgE associated current allergic 
multimorbidity (N = 10 575)
Before puberty
After puberty 
Before puberty
After puberty 
Current rhinitis only (N = 14 533)
Before puberty
After puberty 
Current asthma only (N = 14 533)
Current allergic multimorbidity (N = 14 533) 
Before puberty
After puberty 
Outcome Odds Ratio OR  95%-CI Sex*puberty interaction
P-value 
.089
.327
<.001
.279
.329
<.001
.085
.141
.020
IgE-associated current 
asthma only (N = 10 575)
Before puberty
After puberty 
Before puberty
After puberty 
F IGURE 4 Odds Ratios from one-stage IPD meta-analysis of sex effect (female vs male) before and after puberty for all outcomes
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puberty onset in teenage adolescents who were on average slightly
younger. The theory that allergic sensitization might play a crucial
role in the natural history of rhinitis can be reaffirmed considering
sex differences.34
For asthma prevalence, several mostly cross-sectional evaluations
showed a sex-switch from childhood to adolescence towards a
female predominance.5,7 We could not confirm a complete preva-
lence sex-shift for asthma prevalence, but a rather sex-balanced
prevalence for asthma only after puberty. However, our statistical
power was decreased when examining asthma without coexisting
rhinitis and stratifying it by sensitized and nonsensitized subtypes.
Therefore, we were not able to determine more precisely sex-specific
prevalence differences in these strata. The TRAILS study from the
Netherlands found a sex-shift between 11 and 16 years, but no asso-
ciation with pubertal stages as an explanation for the shift was
found.35 Other than in our study, they investigated asthma regardless
of the presence of rhinitis which may explain the different findings.
Due to the common coexistence of asthma and rhinitis,36 we
aimed at evaluating sex-specific prevalence patterns in multimorbid
patients to reduce the knowledge gap for these more severely
affected patients. In particular, population-based research on sex-
specific prevalence differences among multimorbid patients is scarce.
The few earlier evaluations such as in the MAS37 and BAMSE38
cohorts showed an increasing prevalence of allergic multimorbidity
with age. BAMSE found a male predominance in the prevalence of
multimorbidity until the age of 12 that was confirmed by our analy-
ses of multiple European cohorts. Regardless of allergic sensitization
status, we found a stronger male predominance in the prevalence of
allergic multimorbidity before puberty onset than for the single enti-
ties. In puberty, this clear sex-specific prevalence predominance
decreased and shifted clearly towards a sex-balanced prevalence of
multimorbidity after puberty onset. Based on the difference between
prevalence in both individual morbidities and in multimorbidity, we
hypothesize that this is not an additive effect but that due to the
double burden different mechanisms may play a role.
4.4 | Potential mechanisms
Physiological changes during puberty such as endogenous39 or
exogenous sexual hormones (birth control pills)40 have been pro-
posed as potential determinants. Possible explanations include
anatomical differences,41 differences in the immune response profile
such as increased IgE levels and enhanced cytokine responses in
boys compared to girls in early childhood,41,42 whereas in puberty
and adulthood, female sex steroids are in general associated with
enhanced immune responses and testosterone with dampening
inflammatory responses.43
Sociocultural factors such as different symptom reporting beha-
viour between men and women41 have been suggested as mecha-
nisms behind the gender shift in allergic diseases. These are less of a
concern in childhood as symptoms were parent reported but may
play a role from school age on as teenagers fill out their own study
questionnaires.
5 | CONCLUSIONS
In conclusion, we found the strongest male predominance before
puberty for the prevalence of current allergic multimorbidity and
also, but less pronounced, for current rhinitis and current asthma as
single entities. With increasing age, we saw a “sex-shift” towards
females resulting in a rather sex-balanced prevalence after puberty
onset. This effect was much stronger in multimorbid children who
had both current rhinitis and coexisting asthma than in those with
rhinitis or asthma alone. We observed a larger prevalence shift
towards females in nonsensitized than sensitized subjects.
Further cohort follow-up assessments are required to examine
the hypothesized prevalence sex-switch to a female predominance
regarding the different allergic phenotypes in adulthood.
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